Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
The DOI matches its Crossref record; 61 of the 62 references it cites were found in a registry or an index.
Abstract
Mutations in the p53 tumor suppressor are the most frequently observed genetic alterations in human cancer. The majority of the mutations occur in the core domain which contains the sequence-specific DNA binding activity of the p53 protein (residues 102-292), and they result in loss of DNA binding. The crystal structure of a complex containing the core domain of human p53 and a DNA binding site has been determined at 2.2 angstroms resolution and refined to a crystallographic R factor of 20.5 percent. The core domain structure consists of a beta sandwich that serves as a scaffold for two large loops and a loop-sheet-helix motif. The two loops, which are held together in part by a tetrahedrally coordinated zinc atom, and the loop-sheet-helix motif form the DNA binding surface of p53. Residues from the loop-sheet-helix motif interact in the major groove of the DNA, while an arginine from one of the two large loops interacts in the minor groove. The loops and the loop-sheet-helix motif consist of the conserved regions of the core domain and contain the majority of the p53 mutations identified in tumors. The structure supports the hypothesis that DNA binding is critical for the biological activity of p53, and provides a framework for understanding how mutations inactivate it.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Modification of any of five arginine residues that are hotspots for TP53 mutations in human cancers disables TP53 sequence-specific DNA binding (Cho, et al., 1994).”
From The Mdm network and its regulation of p53 activities: a rheostat of cancer risk (2014) · cites this paper as Cho, et al., 1994
In the citing paper
“Gly-245 in the wild type adopts unusual backbone dihedral angles (1), which are not favored when the residue is replaced by serine.”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
In the citing paper
“The crystal structure of p53 core domain shows that the epitope of PAb240, located in strand 7, is inaccessible to antibody binding (1), and at least a partly unfolded form is required to expose the epitope.”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
In the citing paper
“The guanidinium group of Arg-249 is salt-bridged to the carboxylate group of Glu-171 in L2 and backbone oxygens of Gly-245 and Met-246 (1).”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
In the citing paper
“suggesting the structure of p53 core domain in solution is similar to that in crystal structure (1).”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Kabsch, W., & Sander, C. (1983) · Biopolymers · doi:10.1002/bip.360221211 · Cited by 15,320
Jones, T. A., Zou, J. Y., Cowan, S. W., & Kjeldgaard, M. (1991) · Acta Crystallographica Section A Foundations of Crystallography · doi:10.1107/s0108767390010224 · Cited by 12,648
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Principles of Nucleic Acid Structure
Saenger, W. (1984) · Springer Advanced Texts in Chemistry · doi:10.1007/978-1-4612-5190-3 · Cited by 4,150
The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53
Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J., & Howley, P. M. (1990) · Cell · doi:10.1016/0092-8674(90)90409-8 · Cited by 3,995
The p53 tumour suppressor gene
Levine, A. J., Momand, J., & Finlay, C. A. (1991) · Nature · doi:10.1038/351453a0 · Cited by 3,788
Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., & Fornace, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90593-2 · Cited by 3,047
Research works printed but not linked: 2
- SACK, J. S., JOURNAL OF MOLECULAR GRAPHICS 6: 224 (1988).
- TONRUD, D.E., ACTA CRYSTALLOGR A 43: 489 (1987).
Cited by
Items 2,001–2,100 of 2,517
Villadsen, R., Nielsen, K. V., Bolund, L., et al. (2000) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(99)00112-0 · Cited by 4
Penna, G. L., Mormino, M., Pioli, F., Perico, A., Fioravanti, R., Gruschus, J. M., & Ferretti, J. A. (1999) · Biopolymers · doi:10.1002/(sici)1097-0282(199903)49:3 · Cited by 12
Pharmacogenomics of the p53 tumor suppressor and its role in cancer chemoresistance
Liu, S., Bishop, W. R., Dasmahapatra, B., & Wang, Y. (2004) · Drug Development Research · doi:10.1002/ddr.10362 · Cited by 6
“The p53 DNA binding domain is exceptionally flexible, and conformational flexibility is key to its essential biological roles in tumor suppression [Cho et al., 1994; Lane and Hupp, 2003; Yakovleva et al., 2002].”
BackgroundInfluentialGain-of-function oncogenic mutations in TP53 enhance defined factor-mediated cellular reprogrammingPreprint
Moon, J., Moon, J. H., Ishii, H., Dewi, D. L., Kano, Y., Yamamoto, K., Nishikawa, S., Fujiwara, Y., Doki, Y., & Mori, M. (2011) · Nature Precedings · doi:10.1038/npre.2011.5681.1 · Cited by 3
“Such mutations expose the mutant-specific epitope of the antibody PAb240 but cause a loss of the wild-type-specific epitope that is detected by PAb1620 (13-15).”
BackgroundP53 mutation and LOH at chromosome 9 in urothelial carcinoma.
Beöthe, T., Nagy, A., Farkas, L., & Kovács, G. (2012) · PubMed · Cited by 5
Engelken, J., Altmeyer, M., & FRANKLIN, R. B. (2014) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/002105 · Cited by 4
Regulation of Thyroid Follicular Cell Function by Intracellular Redox-Active Copper
Iseki, A. (2000) · Endocrinology · doi:10.1210/en.141.12.4373 · Cited by 4
Opto-p53: A light-controllable activation of p53 signaling pathway
Tsuruoka, T., Goto, Y., & Aoki, K. (2025) · Cell Structure and Function · doi:10.1247/csf.25017 · Cited by 7
“4 A) (Candau et al. , 1997; Cho et al. , 1994; Joerger et al. , 2005; Lin et al. , 1994; Teufel et al. , 2007; Zhu et al. , 1998).”
A short SUMOylation tag modulates transcription factor activity
Bouchard, A. Y., Vivet, A. J. I., Cabana, V. C., Li, C., Thibault, P., Lussier, M. P., Mader, S., & Cappadocia, L. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.110807 · Cited by 4
Allosteric and Dominant-Negative Effects in a p53 Core Heterotetramer
Zhou, H., Zhou, T., & Yan, S. (2025) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.5c05859 · Cited by 3
Protein–DNA interactions in disease and drug discovery
Mishra, R., & Ahmad, S. (2025) · Chemical Communications · doi:10.1039/d5cc06239j · Cited by 5
Targeting mutant p53 in cancer: from mechanistic insights to therapeutic strategies
Wu, H. H., Leng, S., Eisenstat, D. D., Sergi, C. M., & Leng, R. P. (2026) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-026-00907-x · Cited by 6
“Its presence is often associated with poor prognosis and resistance to conventional therapies [16, 35, 36].”
Mustafa, M., & Gharaibeh, M. A. (2022) · The Protein Journal · doi:10.1007/s10930-022-10041-0 · Cited by 3
“The most frequently mutated residues in the human p53 protein are at or near the p53-DNA interface, specifically, the 2 large loops and the loop-sheet-helix motif (the L1 loop, the 2– 2’turn, the 4 C-terminal residues of 10 strand, and the 2 helix) [85, 89].”
BackgroundS-Nitrosylation of p53 in Melanoma Cells Under Nitrosative Stress
Grigoruţă, M., Li, L., Chen, L., Meng, F., Winfield, J., Rosenblatt, K. P., Li, Y., Grimm, E. A., & Qin, Y. W. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136512 · Cited by 4
p53 in Human Cancer — Somatic and Inherited Mutations and Mutation-independent Mechanisms
Moll, U. M., & Concin, N. (2007) · Springer eBooks · doi:10.1007/0-387-30127-5_6 · Cited by 4
p53’s Dilemma in Transcription: Analysis by Microarrays
Kannan, K., Rechavi, G., & Givol, D. (2010) · Molecular biology intelligence unit · doi:10.1007/978-1-4419-8231-5_10 · Cited by 3
Cannone, J. J., Barnes, C. L., Achari, A., & Kundrot, C. E. (2001) · Journal of Crystal Growth · doi:10.1016/s0022-0248(01)01094-6 · Cited by 3
Relative Stability of Wild-Type and Mutant p53 Core Domain: A Molecular Dynamic Study
Rohani, L., Morton, D. J., Wang, X., & Chaudhary, J. (2015) · Journal of Computational Biology · doi:10.1089/cmb.2015.0163 · Cited by 4
“The 1TSR represents the X-ray crystal structure of a wild-type core domain p53-DNA complex at 2.2 A˚ resolution with a crystallographic R factor of 20.5% (Cho et al., 1994).”
InfluentialMicrobial-Based Therapy of Cancer
Punj, V., Saint‐Dic, D., & Daghfal, S. (2004) · Cited by 3
Chemical principles of DNA sequence recognition and gene regulation
Roy, S., & Kundu, T. K. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-817644-3.00005-2 · Cited by 4
Fuentes, M., Srivastava, S., Gronenborn, A. M., & LaBaer, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010053 · Cited by 3
“At the time of the experiment, these cDNAs are simultaneously transcribed/translated in situ with mammalian ribosomes and the expressed proteins are subsequently captured using the c-terminal epitope tag.”
BackgroundInfluentialKoley, T., Chowdhury, S. R., Kushwaha, T., et al. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.02.108 · Cited by 3
Bizzarri, A. R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012636 · Cited by 4
“The model of the full-length wild-type p53 monomer (393 amino acid residues) was built from the amino acid sequence using the I-TASSER suite [46,47], including the B chain of the DBD portion (94–289 amino acid residues), in complex with a consensus DNA (1TUP entry from the protein data bank) [5].”
MethodA Narrative Review of the TP53 and Its Product the p53 Protein
Foroutan, B. (2023) · OBM Genetics · doi:10.21926/obm.genet.2302185 · Cited by 9
Full-atomistic molecular dynamics analysis of p53 active tetramer
Zhou, H., Geng, Y.-Z., & Yan, S. (2023) · Acta Physica Sinica · doi:10.7498/aps.73.20231515 · Cited by 3
Novel Amodiaquine Analogues to Treat Cervical Cancer and Microbial Infection in the Future
Islam, S., Shahzad, S. A., Asad, M. H. H. B., et al. (2023) · Future Medicinal Chemistry · doi:10.4155/fmc-2023-0245 · Cited by 3
Computational approaches for identifying disease-causing mutations in proteins
Pandey, M., Shah, S. K., & Gromiha, M. M. (2023) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2023.11.007 · Cited by 3
Islam, S. M., Hasan, M. M., Alam, J., Dey, A., & Molineaux, D. (2024) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.26747 · Cited by 5
“The TAD, PRD, DBD, TMD, and RGD domains range from residues 1– 63, residues 63– 97, residues 102– 292, residues 323– 356, and residues 363– 393, respectively (Figure 2B) [9– 11].”
Zhou, H., & Yan, S. (2024) · The Journal of Physical Chemistry Letters · doi:10.1021/acs.jpclett.4c02382 · Cited by 3
Gunathilaka, M. D. T. L., Kumarasinghe, H. S., Bandaranayake, U., Athapaththu, M., Samarakoon, K. W., Ranasinghe, P., & Peiris, L. D. C. (2025) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-025-01685-7 · Cited by 5
“The grid map coordinates for the p53 protein were set as 59.54738, 38.4889, and 54.9798 for x,y, and z dimensions respectively using the active site amino acids composition [17].”
InfluentialThe Oncogenic Activity of p53 Mutants
Sigal, A., & Rotter, V. (2007) · Springer eBooks · doi:10.1007/0-387-30127-5_9 · Cited by 3
p53 Expression in Pterygium Amongst Natives of High Versus Low Altitude
Anthwal, D., & Gupta, M. (2017) · International Journal of Ophthalmology & Eye Science · doi:10.19070/2332-290x-1700068 · Cited by 3
Evolutionary Action Score of TP53 Enhances the Prognostic Prediction for Stage I Lung Adenocarcinoma
Zhao, Y., Han, H., Gao, Z., Hu, H., Xiang, J., Sun, Y., & Chen, H. (2020) · Seminars in Thoracic and Cardiovascular Surgery · doi:10.1053/j.semtcvs.2020.04.005 · Cited by 3
Solution structure of the anticancer p28 peptide in biomimetic medium
Cantini, F., Giannì, P., Savarin, P., Bizzarri, A. R., & Sette, M. (2021) · Journal of Peptide Science · doi:10.1002/psc.3357 · Cited by 3
“Both NTD and CTD are largely unfolded, while DBD has a relatively stable structure.(2) In particular, DBD is characterized by a β-sandwich, formed by two antiparallel β-sheets with a small β-hairpin in contact with one of the two”
BackgroundThe DNA Damage Response Mediates Apoptosis and Tumor Suppression
Baran, K., Rodríguez, D. A., & Green, D. R. (2013) · Springer eBooks · doi:10.1007/978-1-4614-9302-0_7 · Cited by 8
“The core region of p53 consists of its DNA-binding domain (DBD) and is also the region in which many cancer-associated mutations are found [ 88 ].”
BackgroundModes of p53 Interactions with DNA in the Chromatin Context
Vukojević, V. B., Yakovleva, T., & Bakalkin, G. Y. (2010) · Molecular biology intelligence unit · doi:10.1007/978-1-4419-8231-5_9 · Cited by 3
Levine, A. J., Bargonetti, J., Bond, G. L., Hoh, J. J., Onel, K., Overholtzer, M., Stoffel, A., Teresky, A. K., Walsh, C. A., & Jin, S. (2005) · Springer eBooks · doi:10.1007/0-387-30127-5_1 · Cited by 4
Signal transduction: Fast lane to transcriptional activation
Rhodes, D., & Schwabe, J. W. R. (1998) · Current Biology · doi:10.1016/s0960-9822(07)00481-2 · Cited by 3
Liu, C., Liang, G., Liu, Z., & Zu, L. (2013) · Journal of Fluorescence · doi:10.1007/s10895-013-1322-7 · Cited by 3
“The truncated peptide contains the amino acid residues (Arg273, Ala276, Cys277, Arg280, Arg283) which interacting with the bases and the backbone of DNA at the major groove side [2, 9].”
Kovvali, G. K., Mehta, B., Epstein, C. B., & Lutzker, S. G. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.5.e28 · Cited by 4
“A yeast expression plasmid containing a human wild-type p53 cDNA (pLS76) and a version of this plasmid with an outof-frame internal deletion in the p53 cDNA (pRDI-22) were obtained from R.Iggo.”
BackgroundInfluentialA novel mutation of p63 in a Chinese family with inherited syndactyly and adactylism
Luo, T., Yu, W., Yuan, Z., Deng, Y., Zhao, Y., Yuan, W., Xiao, J., Wang, Y., Luo, N., Mo, X., et al. (2007) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2007.08.010 · Cited by 3
Accumulation of class I mutant p53 and apoptosis induced by carboplatin in a human glioma cell line
Hamada, Y., Mizoguchi, M., Suzuki, S. O., & Iwaki, T. (1998) · Brain Tumor Pathology · doi:10.1007/bf02478887 · Cited by 3
p53 arrests growth and induces differentiation of v-Myb-transformed monoblasts
Navrátilová, J., Horváth, V., Kozubı́k, A., Lojek, A., Lipsick, J. S., & Šmarda, J. (2007) · Differentiation · doi:10.1111/j.1432-0436.2006.00158.x · Cited by 3
Differential effects of novel tumour-derived p53 mutations on the transformation of NIH-3T3 cells
Donninger, H., Binder, A. B., Böhm, L., & Parker, M. I. (2007) · Biological Chemistry · doi:10.1515/bc.2008.010 · Cited by 4
Zn finger proteins: Key ways for metalloregulation
Kudrin, A. V. (2002) · The Journal of Trace Elements in Experimental Medicine · doi:10.1002/jtra.10007 · Cited by 3
Mirzayans, R., & Murray, D. L. (2008) · The Open Cancer Journal · doi:10.2174/1874079000802010042 · Cited by 3
“The human p53 tumor suppressor is a 393 amino acid tetrameric transcription factor consisting of five structural and functional domains: an N-terminal acidic transcriptional transactivation domain, a proline-rich regulatory domain, a central DNA-binding domain, an oligomerization domain, and a C-terminal domain involv…”
BackgroundA step closer toward therapies for p63-related disorders
Zhou, H., & Aberdam, D. (2013) · Rare Diseases · doi:10.4161/rdis.24247 · Cited by 3
Getting Phosphorylated: Is it Necessary to be Solvent Accessible ?
Kumar, N. (2015) · Revista de Fomento Social · doi:10.16943/ptinsa/2015/v81i2/48102 · Cited by 3
Taja‐Chayeb, L., Vidal-Millán, S., Gutiérrez, O., Trejo‐Becerril, C., Pérez‐Cárdenas, E., Chávez-Blanco, A. D., la Cruz-Hernández, E. N. D., & Dueñas‐González, A. (2009) · World Journal of Surgical Oncology · doi:10.1186/1477-7819-7-97 · Cited by 3
“The majority of missense alterations occur at evolutionarily conserved amino acid residues in the DNA binding domain [7]; outside of this core region, deleterious TP53 changes tend to be nonsense or frameshift mutations that cause premature protein-translation termination [8-10].”
BackgroundPOLYMERIZATION OF THE DNA BINDING FRAGMENT OF p53 ON DNA: ATOMIC FORCE MICROSCOPY STUDY
Lyubchenko, Y. L., Shlyakhtenko, L. S., Nagaich, A. K., Appella, E., Harrington, R. E., & Lindsay, S. M. (1998) · Cited by 3
La proteína p53 en procesos neurodegerativos en sus 25 años de historia
Gómez-Lázaro, M., Fernández-Gómez, F.-J., & Bueso, J. J. (2004) · Revista de Neurología · doi:10.33588/rn.3903.2004355 · Cited by 7
New insights into transcriptional and leukemogenic mechanisms of AML1-ETO and E2A fusion proteins
Li, J., Guo, C. H., Steinauer, N., & Zhang, J. (2016) · Frontiers in Biology · doi:10.1007/s11515-016-1415-1 · Cited by 4
“Overall, RHD assumes an all-β structure characteristic of the S-type immunoglobulin (Ig) fold that is also observed in DNA binding domains of p53 and NF k B (Cho et al., 1994; Chen et al., 1998; Nagata et al., 1999).”
Zinc and Zinc-Dependent Proteins in Cancer and Chemotherapeutics
Guynn, J. M., & Chan, E. (2017) · Molecular and integrative toxicology · doi:10.1007/978-3-319-55448-8_4 · Cited by 4
Wasserman, J. K., AlGhamdi, D. A., de Almeida, J. R., Stockley, T. L., & Perez‐Ordoñez, B. (2018) · Head and Neck Pathology · doi:10.1007/s12105-018-0934-2 · Cited by 3
Proteasome Inhibitors in Cancer Therapy and their Relation to Redox Regulation
Sarı, G., Okat, Z., Şahin, A., & Karademir-Yilmaz, B. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190201120013 · Cited by 5
Morgunkova, A. A., Almazov, V. P., Strunina, S. M., Kopnin, B. P., & Chumakov, P. M. (2003) · Molecular Biology · doi:10.1023/a:1022393031857 · Cited by 3
“Apparently, such a mutation allows tumor progression, which is accompanied by uncontrollable selection of cells having a selective advantage [4, 5].”
BackgroundOn the regulation of the p53 tumour suppressor, and its role in the cellular response to DNA damage
Lane, D. P., MIDGLEY, C. A., Hupp, T. R., et al. (1995) · Springer eBooks · doi:10.1007/978-94-011-0537-8_12 · Cited by 3
Sarkar, S. (2023) · Physiologia · doi:10.3390/physiologia3010002 · Cited by 4
Targeting the MDM2–p53 Protein–Protein Interaction
Hardcastle, I. R. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-396521-9.00013-9 · Cited by 3
Murphy, M. E., & Levine, A. J. (1998) · Springer eBooks · doi:10.1007/978-1-4615-5287-1_2 · Cited by 4
The use of Sphingomyelin to protect against UV induced DNA damage in Human Keratinocytes
Campbell, K. (2015) · DigitalCommons - CalPoly (California State Polytechnic University) · doi:10.15368/theses.2015.72 · Cited by 3
Transcriptional repression in normal human keratinocytes by wild-type and mutant p53
Álvarez-Salas, L. M., Velazquez, A., López‐Bayghen, E., Woodworth, C. D., Garrido, E., Gariglio, P., & DiPaolo, J. A. (1995) · Cancer Letters · doi:10.1016/0304-3835(95)03721-8 · Cited by 5
Wagner, P. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.t01-1-00441.x · Cited by 3
Portefaix, J.-M., Rio, M. D., Granier, C., et al. (2003) · Peptides · doi:10.1016/s0196-9781(03)00047-0 · Cited by 3
p53 as a target for improved cancer therapy
Wiman, K. G. (1999) · Emerging Therapeutic Targets · doi:10.1517/14728222.3.2.347 · Cited by 3
Functional Rescue of Mutant p53 as a Strategy to Combat Cancer
Selivanova, G., & Wiman, K. G. (2002) · Elsevier eBooks · doi:10.1016/b978-012476249-7/50021-7 · Cited by 3
Chromosome 18q allelic loss and prognosis in stage II and III colon cancer
Lanza, G., Matteuzzi, M., Gafá, R., Orvieto, E., Maestri, I., Santini, A., & del Senno, L. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19980821)79:4<390::aid-ijc14>3.0.co;2-9 · Cited by 141
Hoos, A., Hepp, H. H., Kaul, S., Ahlert, T., Bastert, G., & Wallwiener, D. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19980220)79:1<8::aid-ijc2>3.0.co;2-5 · Cited by 72
Sugino, T., Yoshida, K., Bolodeoku, J., Tahara, H., Buley, I., Manek, S., Wells, C., Goodison, S., Ide, T., Suzuki, T., et al. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19960822)69:4<301::aid-ijc11>3.0.co;2-8 · Cited by 115
Structural changes from wild-type define tumor-rejecting neoantigens
Adams, A. C., Macy, A. M., Borden, E. S., Herrmann, L. M., Brambley, C. A., Sonar, S. A., Ma, T., Li, X., Hughes, A., Roe, D. J., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-013148 · Cited by 4
Niknejad, A., Esmaealzadeh, N., Peyrovinasab, A., Sirouskabiri, S., Gholami, M., Pasha, A. V. K., Shahri, S., Büsselberg, D., & Abdolghaffari, A. H. (2025) · Phytotherapy Research · doi:10.1002/ptr.8522 · Cited by 3
“The presence of these hotspot residues can be explained by the vulnerability of specific codons to alterations induced by carcinogens and by the positive selection of mutations that confer growth and survival advantages to the cell (Cho et al. 1994).”
The relationship between copper metabolism and p53 activity in tumors
Yu, W., Hong, X., Wang, G., Zhong, C., Yan, Y., Ma, Q., Lai, Y., Zhu, N., Chen, X., Li, N., et al. (2025) · Metallomics · doi:10.1093/mtomcs/mfaf025 · Cited by 3
Zhao, L., Punga, T., & Sanyal, S. (2025) · eLife · doi:10.7554/elife.106469.2 · Cited by 10
LT1-3, a Slit2-Derived Peptide, Exhibits Anti-Tumor Activity and Improves Cisplatin Therapy
Wu, T.-C., Liao, C.-Y., Lin, Y.-Y., Chuang, S.-M., Liu, S.-Y., Wang, C.-H., Su, S.-E., Wu, S.-W., Wang, L.-I., Chen, W., et al. (2025) · Cells · doi:10.3390/cells14211654 · Cited by 2
Feature Multiplexing—Improving the Efficiency of Microarray Devices
Schmid, M. J., Manthiram, K., Grayson, S. M., et al. (2006) · Angewandte Chemie · doi:10.1002/ange.200502151 · Cited by 2
Somatic mutations in SF3B1 aberrant‐negative MDS‐RS most commonly involved in TP53 genes
Li, X., Xu, F., Wu, L., Guo, J., He, Q., & Zhang, Z. (2022) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17350 · Cited by 2
Pratap, A., Lim, E.-J., Kwak, I., & Moon, B.-S. (2022) · Organoid · doi:10.51335/organoid.2022.2.e8 · Cited by 2
“Specifically, p53 is a tumor suppressor gene that is important for the binding and recognition of DNA damage, ultimately stimulating p21, blocking cdk2, and causing cell cycle arrest [18].”
BackgroundWakasa, T., Nonaka, K., Harada, A., Ohkawa, Y., Kikutake, C., Suyama, M., Kobunai, T., Tsunekuni, K., Matsuoka, K., Kataoka, Y., et al. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-02083-3 · Cited by 4
“These mutations were classi fi ed into structural (R175H) and DNA-contacting (R248Q) mutations, which are the most frequently encountered p53-targeting mutations in human cancer [11, 27].”
Cai, B., Wang, Y.-T., Chen, C., Yeh, F.-Y., Lin, Y.-R., Lin, Y.-C., Wu, T.-Y., Wu, K.-Y., Lien, C., Shih, Y., et al. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2025.167662 · Cited by 4
Mutant p53 regulates a distinct gene set by a mode of genome occupancy that is shared with wild type
Rahmé, R., Resnick‐Silverman, L., Anguiano, V., Campbell, M. J., Fenaux, P., & Manfredi, J. J. (2025) · EMBO Reports · doi:10.1038/s44319-025-00375-y · Cited by 3
“…and fail to occupy wild type p53 binding sites that conform to the well characterized consensus (Bargonetti et al, 1991; Bargonetti et al, 1993; Cho et al, 1994; el-Deiry et al, 1992; Joerger et al, 2006; Joerger et al, 2005; Kato et al, 2003; Kennedy and Lowe, 2022; Kern et al, 1991a; Kern et…”
Osbourne, R., & Thayer, K. M. (2025) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1012382 · Cited by 2
“In these lopped regions, RPLARs may play an important role in DNA recognition, binding, and maintaining p53’s structural integrity [26].”
TP53 Germline Mutations: Genetics of Li–Fraumeni Syndrome
Bakry, D., & Malkin, D. M. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3676-8_10 · Cited by 4
The Regulation of p53 Protein Function by Phosphorylation
MacLaine, N. J., & Hupp, T. (2010) · Molecular biology intelligence unit · doi:10.1007/978-1-4419-8231-5_4 · Cited by 2
p53-Deficient Medaka Created by TILLING
Taniguchi, Y. (2011) · Springer eBooks · doi:10.1007/978-4-431-92691-7_10 · Cited by 2
New Insights into P53 Signalling and Cancer: Implications for Cancer Therapy
Nigro, C. L. (2014) · Journal of Tumor · Cited by 2
Mutant p53 Reactivation as a Novel Strategy for Cancer Therapy
Selivanova, G., Bykov, V. J. N., & Wiman, K. G. (2005) · Springer eBooks · doi:10.1007/978-1-4020-2922-6_18 · Cited by 3
“Interestingly, the Phe-176 mutant p53 which lacks Cys-176 that holds a Zn atom critical for the structural integrity of the DNA binding domain ( Cho et al. 1994 ) was refractory to reactivation by PRIMA-1.”
BackgroundXue, Y., Wang, S., & Feng, X. (2009) · Chinese Journal of Analytical Chemistry · doi:10.1016/s1872-2040(08)60122-x · Cited by 2
An affinity purification procedure to isolate oxidized p53
Scotcher, J., Clarke, D. J., & Langridge‐Smith, P. R. R. (2011) · Analytical Biochemistry · doi:10.1016/j.ab.2011.08.049 · Cited by 2
Chitayat, S., & Arrowsmith, C. H. (2010) · Nature Structural & Molecular Biology · doi:10.1038/nsmb0410-390 · Cited by 3
Loss of TP53-DNA interaction induced by p.C135R in lung cancer
Aranda, M., González-Nilo, F. D., Riadi, G., Díaz, V., Perez, J., Martel‐Planche, G., Hainaut, P. L., & Mimbacas, A. (2007) · Oncology Reports · doi:10.3892/or.18.5.1213 · Cited by 2
Novel anti-cancer compounds: Structure-based discovery of chemical chaperons for p53
Kuwata (2009) · Oncology Reports · doi:10.3892/or_00000495 · Cited by 2
Jacob, S. G., & Ramani, R. G. (2015) · Cited by 2
Transformation by Polyomaviruses
Das, D., & Imperiale, M. J. (2008) · Springer eBooks · doi:10.1007/978-0-387-68945-6_2 · Cited by 3
Detection of Point Mutations of K-ras Oncogene and p53 Tumor-Suppressor Gene in Sputum Samples
Gao, W., & Keohavong, P. (2014) · Methods in molecular biology · doi:10.1007/978-1-62703-739-6_26 · Cited by 2
Cluster Analysis of p53 Binding Site Sequences Reveals Subsets with Different Functions
Lim, J., Latysheva, N. S., Iggo, R. D., & Barker, D. (2016) · Cancer Informatics · doi:10.4137/cin.s39968 · Cited by 2
“p53 binds to these sites as a 68 homotetrameric ‘dimer of dimers’, where each dimer interacts with a redundant, approximately 69 palindromic, decameric DNA motif called the p53 response element (RE).(10,11,12,13,14) The two 70”
BackgroundChemical principles additive model aligns low consensus DNA targets of p53 tumor suppressor protein
Thayer, K. M., & Han, I. S. M. (2017) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2017.03.003 · Cited by 2
Yuan, X., Jia, X.-Y., Li, H., Yu, X., & Wu, Y. (2017) · RSC Advances · doi:10.1039/c7ra05630c · Cited by 2
p53 gene cloning and response to hypoxia in the plateau zokor, Myospalax baileyi
An, Z., Zhao, K. F., Wei, L., Wang, Z., Li, S., Wei, L., & Wei, D. (2018) · Animal Biology · doi:10.1163/15707563-18000004 · Cited by 2
“In p53, these mutations cause a loss of wild-type p53 tumour suppressor activity and promote tumourigenesis, resulting in cell cycle G1 arrest in cells (Cho et al., 1994; Hollstein et al., 1994; Vousden & Lu, 2002; Menendez et al., 2006).”
BackgroundYu, X., & Carpizo, D. R. (2019) · Oncotarget · doi:10.18632/oncotarget.26561 · Cited by 2
Choudhuri, S., Arvidson, K. B., & Chanderbhan, R. F. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-385926-6.00026-0 · Cited by 2
Metadata
- Authors
- Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Venue
- Science
- Published
- 1994-07-15
- Volume
- 265
- Issue
- 5170
- Pages
- 346-355
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2096276671
- Semantic Scholar
- 11096f3b08e172ce5e261795b6749818ee59c03d
- Cited by
- 2,551
- References
- 62
- Citations by year
- 2026: 62 · 2025: 52 · 2024: 40 · 2023: 64 · 2022: 61 · 2021: 73 · 2020: 67 · 2019: 62 · 2018: 61 · 2017: 54 · 2016: 64 · 2015: 62 · 2014: 81 · 2013: 78 · 2012: 68
- FWCI
- 64.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Open Access System for Information Sharing (Pohang University of Science and Technology) (submittedVersion)
- Funders
- National Cancer Institute (NCI CA08748-29)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Structure and Dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Structural Biology › Enzyme Structure and Function
- Keywords
- p53 tumor suppressor, p53 core domain, DNA binding, zinc coordination, beta-sandwich, cancer genetics
- MeSH terms
- Amino Acid Sequence, Base Sequence, Binding Sites, Computer Graphics, Crystallization, DNA, Hydrogen Bonding, Models, Molecular, Molecular Sequence Data, Mutation, Nucleic Acid Conformation, Protein Conformation, Genes, p53, Tumor Suppressor Protein p53, Protein Structure, Secondary, Crystallography, X-Ray
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.